{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:15:50Z","timestamp":1791346550006,"version":"4.3.1"},"reference-count":249,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK 2254\/1"],"award-info":[{"award-number":["GRK 2254\/1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70114761"],"award-info":[{"award-number":["70114761"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["KL 2544\/6\\u20131"],"award-info":[{"award-number":["KL 2544\/6\\u20131"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.addr.2025.115697","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T09:58:59Z","timestamp":1757757539000},"page":"115697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Tumor microenvironment subtyping in pancreatic ductal adenocarcinoma: New avenues for personalized therapeutic strategies"],"prefix":"10.1016","volume":"226","author":[{"given":"Dharini","family":"Srinivasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Gout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kleger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4930-6292","authenticated-orcid":false,"given":"Elodie","family":"Roger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2025","key":"10.1016\/j.addr.2025.115697_b0005","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.addr.2025.115697_b0010","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.addr.2025.115697_b0015","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"Canadian Cancer Trials, G.I.P.G. the Unicancer, FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2025.115697_b0020","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2025.115697_b0025","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2025.115697_b0030","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1136\/gutjnl-2019-319984","article-title":"DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives","volume":"70","author":"Perkhofer","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.addr.2025.115697_b0035","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2025.115697_b0040","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16101808","article-title":"Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy","volume":"16","author":"Olaoba","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115697_b0045","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41401-020-00584-2","article-title":"Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications","volume":"42","author":"Hu","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.addr.2025.115697_b0050","first-page":"2969","article-title":"Progression model for pancreatic cancer","volume":"6","author":"Hruban","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115697_b0055","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.1158\/1078-0432.CCR-12-1215","article-title":"Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors","volume":"18","author":"Yachida","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115697_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246188","article-title":"Tumor Microenvironment in Pancreatic Intraepithelial Neoplasia","volume":"13","author":"Opitz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115697_b0065","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1755-1536-6-20","article-title":"Matrix regulation of idiopathic pulmonary fibrosis: the role of enzymes","volume":"6","author":"Clarke","year":"2013","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.addr.2025.115697_b0070","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.612271","article-title":"Stroma Involvement in Pancreatic Ductal Adenocarcinoma: an Overview focusing on Extracellular Matrix Proteins","volume":"12","author":"Liot","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2025.115697_b0075","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082354","article-title":"Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: challenges and Opportunities","volume":"15","author":"Myo Min","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115697_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2024.111584","article-title":"The multi-faceted roles of cancer-associated fibroblasts in pancreatic cancer","volume":"127","author":"Kwon","year":"2025","journal-title":"Cell. Signal."},{"key":"10.1016\/j.addr.2025.115697_b0085","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"25","author":"Ozdemir","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2025.115697_b0090","doi-asserted-by":"crossref","first-page":"e3033","DOI":"10.1038\/cddis.2017.424","article-title":"Acceleration of pancreatic tumorigenesis under immunosuppressive microenvironment induced by Reg3g overexpression","volume":"8","author":"Liu","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.addr.2025.115697_b0095","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/0008-5472.CAN-18-1334","article-title":"Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma","volume":"79","author":"Elahi-Gedwillo","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115697_b0100","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.molmed.2023.03.002","article-title":"Fibroblasts in pancreatic cancer: molecular and clinical perspectives","volume":"29","author":"Rebelo","year":"2023","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.addr.2025.115697_b0105","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","article-title":"Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma","volume":"25","author":"Rhim","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2025.115697_b0110","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1053\/j.gastro.2011.12.042","article-title":"Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia","volume":"142","author":"Kanda","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2025.115697_b0115","doi-asserted-by":"crossref","unstructured":"J.L. Kopp, G. von Figura, E. Mayes, F.F. Liu, C.L. Dubois, J.P.t. Morris, F.C. Pan, H. Akiyama, C.V. Wright, K. Jensen, M. Hebrok, M. Sander, Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma, Cancer Cell, 22 (2012) 737-750.","DOI":"10.1016\/j.ccr.2012.10.025"},{"key":"10.1016\/j.addr.2025.115697_b0120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2025.115697_b0125","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","article-title":"Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance","volume":"18","author":"Sherman","year":"2023","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.addr.2025.115697_b0130","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1158\/2159-8290.CD-19-0435","article-title":"MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype","volume":"10","author":"Sodir","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2025.115697_b0135","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1016\/j.cell.2021.09.022","article-title":"Spatially confined sub-tumor microenvironments in pancreatic cancer","volume":"184","author":"Grunwald","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.addr.2025.115697_b0140","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","article-title":"Pancreatic cancer stroma: an update on therapeutic targeting strategies","volume":"17","author":"Hosein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.addr.2025.115697_b0145","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41568-018-0038-z","article-title":"Every step of the way: integrins in cancer progression and metastasis","volume":"18","author":"Hamidi","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2025.115697_b0150","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1038\/s41467-021-22490-9","article-title":"Suppression of pancreatic ductal adenocarcinoma growth and metastasis by fibrillar collagens produced selectively by tumor cells","volume":"12","author":"Tian","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115697_b0155","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1021\/pr4010184","article-title":"Quantitative glycoproteomics analysis reveals changes in N-glycosylation level associated with pancreatic ductal adenocarcinoma","volume":"13","author":"Pan","year":"2014","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.addr.2025.115697_b0160","doi-asserted-by":"crossref","first-page":"19609","DOI":"10.1073\/pnas.1908626116","article-title":"Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells","volume":"116","author":"Tian","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2025.115697_b0165","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1471-2407-13-154","article-title":"Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop","volume":"13","author":"Ohlund","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.addr.2025.115697_b0170","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.ccell.2022.06.011","article-title":"Oncogenic collagen I homotrimers from cancer cells bind to alpha3beta1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer","volume":"40","author":"Chen","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2025.115697_b0175","doi-asserted-by":"crossref","first-page":"16031","DOI":"10.1038\/ncomms16031","article-title":"Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions","volume":"8","author":"Olivares","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115697_b0180","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41556-018-0131-2","article-title":"Mechanisms and impact of altered tumour mechanics","volume":"20","author":"Mohammadi","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.addr.2025.115697_b0185","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/0008-5472.CAN-19-0454","article-title":"Meflin-positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis","volume":"79","author":"Mizutani","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115697_b0190","doi-asserted-by":"crossref","first-page":"65982","DOI":"10.18632\/oncotarget.11786","article-title":"Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells","volume":"7","author":"Nagathihalli","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.addr.2025.115697_b0195","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/labinvest.2014.10","article-title":"Fibrogenesis in pancreatic cancer is a dynamic process regulated by macrophage-stellate cell interaction","volume":"94","author":"Shi","year":"2014","journal-title":"Lab. Invest."},{"key":"10.1016\/j.addr.2025.115697_b0200","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1136\/gutjnl-2013-306271","article-title":"Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity","volume":"63","author":"Stromnes","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.addr.2025.115697_b0205","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00262-014-1527-x","article-title":"Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer","volume":"63","author":"Panni","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.addr.2025.115697_b0210","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/gutjnl-2016-312078","article-title":"Myeloid cells are required for PD-1\/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer","volume":"66","author":"Zhang","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.addr.2025.115697_b0215","doi-asserted-by":"crossref","first-page":"12493","DOI":"10.1073\/pnas.0601807103","article-title":"Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis","volume":"103","author":"Nozawa","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2025.115697_b0220","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11040564","article-title":"Tumor-Associated Neutrophils in Cancer: going pro","volume":"11","author":"Wu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115697_b0225","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1038\/s41467-021-23731-7","article-title":"Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade","volume":"12","author":"Nielsen","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115697_b0230","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1158\/0008-5472.CAN-22-1190","article-title":"Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma reveals Tumor Microenvironment Heterogeneity and Prognostic Biomarkers","volume":"82","author":"Mi","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115697_b0235","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2592419","article-title":"The Role of Tumor-Infiltrating B Cells in Tumor Immunity","volume":"2019","author":"Guo","year":"2019","journal-title":"J. Oncol."},{"key":"10.1016\/j.addr.2025.115697_b0240","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1085147","article-title":"Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma","volume":"5","author":"Castino","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.addr.2025.115697_b0245","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1158\/2159-8290.CD-20-0841","article-title":"Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome","volume":"11","author":"Liudahl","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2025.115697_b0250","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1158\/2159-8290.CD-21-0601","article-title":"Mesenchymal Lineage Heterogeneity Underlies Nonredundant Functions of Pancreatic Cancer-Associated Fibroblasts","volume":"12","author":"Helms","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2025.115697_b0255","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature06188","article-title":"Mesenchymal stem cells within tumour stroma promote breast cancer metastasis","volume":"449","author":"Karnoub","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.addr.2025.115697_b0260","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","article-title":"IL1-Induced JAK\/STAT Signaling is Antagonized by TGFbeta to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma","volume":"9","author":"Biffi","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2025.115697_b0265","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202415756","article-title":"PLXDC1(+) Tumor-Associated Pancreatic Stellate Cells Promote Desmoplastic and Immunosuppressive Niche in Pancreatic Ductal Adenocarcinoma","author":"Du","year":"2025","journal-title":"Adv Sci (weinh)"},{"key":"10.1016\/j.addr.2025.115697_b0270","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ccell.2022.04.011","article-title":"Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer","volume":"40","author":"Huang","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2025.115697_b0275","first-page":"581","article-title":"Differential Contribution of Pancreatic Fibroblast Subsets to the Pancreatic Cancer Stroma, Cell Mol","volume":"10","author":"Garcia","year":"2020","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.addr.2025.115697_b0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-34464-6","article-title":"The splanchnic mesenchyme is the tissue of origin for pancreatic fibroblasts during homeostasis and tumorigenesis","volume":"14","author":"Han","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115697_b0285","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.cell.2023.03.016","article-title":"Fibroblasts in cancer: Unity in heterogeneity","volume":"186","author":"Chhabra","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.addr.2025.115697_b0290","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1084\/jem.20162024","article-title":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","volume":"214","author":"Ohlund","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.addr.2025.115697_b0295","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ccell.2023.12.002","article-title":"EGFR-activated myofibroblasts promote metastasis of pancreatic cancer","volume":"42","author":"Mucciolo","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2025.115697_b0300","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","article-title":"Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma reveals Antigen-Presenting Cancer-Associated Fibroblasts","volume":"9","author":"Elyada","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2025.115697_b0305","doi-asserted-by":"crossref","first-page":"10534","DOI":"10.1038\/s41467-024-54975-8","article-title":"Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer","volume":"15","author":"Veghini","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115697_b0310","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/path.5224","article-title":"Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma","volume":"248","author":"Neuzillet","year":"2019","journal-title":"J. Pathol."},{"key":"10.1016\/j.addr.2025.115697_b0315","doi-asserted-by":"crossref","first-page":"9405","DOI":"10.1096\/fj.201902990R","article-title":"CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma","volume":"34","author":"Awaji","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.addr.2025.115697_b0320","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41421-021-00271-4","article-title":"Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response","volume":"7","author":"Wang","year":"2021","journal-title":"Cell Discov"},{"key":"10.1016\/j.addr.2025.115697_b0325","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1158\/2159-8290.CD-19-0644","article-title":"Single-Cell RNA Sequencing reveals Stromal Evolution into LRRC15(+) Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy","volume":"10","author":"Dominguez","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2025.115697_b0330","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.addr.2025.115697_b0335","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.addr.2025.115697_b0340","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146987","article-title":"Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts","volume":"131","author":"Bhattacharjee","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2025.115697_b0345","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","article-title":"Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer","volume":"62","author":"Jacobetz","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.addr.2025.115697_b0350","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2025.115697_b0355","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115697_b0360","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized phase III Trial of Pegvorhyaluronidase Alfa with Nab-Paclitaxel Plus Gemcitabine for patients with Hyaluronan-High Metastatic Pancreatic Adenocarcinoma","volume":"38","author":"Van Cutsem","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115697_b0365","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030628","article-title":"Prognostic significance of Integrin Subunit Alpha 2 (ITGA2) and Role of Mechanical Cues in Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma (PDAC)","volume":"15","author":"Gregori","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115697_b0370","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16223863","article-title":"Altered Mechanobiology of PDAC Cells with acquired Chemoresistance to Gemcitabine and Paclitaxel","volume":"16","author":"Gregori","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115697_b0375","doi-asserted-by":"crossref","unstructured":"C. Vennin, P. Melenec, R. Rouet, M. Nobis, A.S. Cazet, K.J. Murphy, D. Herrmann, D.A. Reed, M.C. Lucas, S.C. Warren, Z. Elgundi, M. Pinese, G. Kalna, D. Roden, M. Samuel, A. Zaratzian, S.T. Grey, A. Da Silva, W. Leung, I. Australian Pancreatic Genome, S. Mathivanan, Y. Wang, A.W. Braithwaite, D. Christ, A. Benda, A. Parkin, P.A. Phillips, J.M. Whitelock, A.J. Gill, O.J. Sansom, D.R. Croucher, B.L. Parker, M. Pajic, J.P. Morton, T.R. Cox, P. Timpson, CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan, Nat Commun, 10 (2019) 3637.","DOI":"10.1038\/s41467-019-10968-6"},{"key":"10.1016\/j.addr.2025.115697_b0380","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1158\/0008-5472.CAN-19-2578","article-title":"Cancer Cell-Derived Matrisome Proteins Promote Metastasis in Pancreatic Ductal Adenocarcinoma","volume":"80","author":"Tian","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115697_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216345","article-title":"Hypoxia induces immunosuppression, metastasis and drug resistance in pancreatic cancers","volume":"571","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.addr.2025.115697_b0390","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.neo.2016.09.003","article-title":"Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer","volume":"18","author":"Lee","year":"2016","journal-title":"Neoplasia"},{"key":"10.1016\/j.addr.2025.115697_b0395","doi-asserted-by":"crossref","unstructured":"C. Vennin, V.T. Chin, S.C. Warren, M.C. Lucas, D. Herrmann, A. Magenau, P. Melenec, S.N. Walters, G. Del Monte-Nieto, J.R. Conway, M. Nobis, A.H. Allam, R.A. McCloy, N. Currey, M. Pinese, A. Boulghourjian, A. Zaratzian, A.A. Adam, C. Heu, A.M. Nagrial, A. Chou, A. Steinmann, A. Drury, D. Froio, M. Giry-Laterriere, N.L. Harris, T. Phan, R. Jain, W. Weninger, E.J. McGhee, R. Whan, A.L. Johns, J.S. Samra, L. Chantrill, A.J. Gill, M. Kohonen-Corish, R.P. Harvey, A.V. Biankin, I. Australian Pancreatic Cancer Genome, T.R. Evans, K.I. Anderson, S.T. Grey, C.J. Ormandy, D. Gallego-Ortega, Y. Wang, M.S. Samuel, O.J. Sansom, A. Burgess, T.R. Cox, J.P. Morton, M. Pajic, P. Timpson, Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis, Sci Transl Med, 9 (2017).","DOI":"10.1126\/scitranslmed.aai8504"},{"key":"10.1016\/j.addr.2025.115697_b0400","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41419-021-03420-5","article-title":"Correction: Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1\/SATB-1 pathway in pancreatic cancer","volume":"12","author":"Wei","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.addr.2025.115697_b0405","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.canlet.2019.04.002","article-title":"Cancer-associated fibroblasts-derived IL-8 mediates resistance to cisplatin in human gastric cancer","volume":"454","author":"Zhai","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.addr.2025.115697_b0410","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1038\/s41598-020-62416-x","article-title":"Metastasis-associated fibroblasts promote angiogenesis in metastasized pancreatic cancer via the CXCL8 and the CCL2 axes","volume":"10","author":"Pausch","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115697_b0415","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/carcin\/bgw093","article-title":"TGF-beta-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3","volume":"37","author":"Hesler","year":"2016","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.addr.2025.115697_b0420","doi-asserted-by":"crossref","first-page":"6851","DOI":"10.1158\/0008-5472.CAN-16-1201","article-title":"Chemoresistance in Pancreatic Cancer is Driven by Stroma-Derived Insulin-like Growth Factors","volume":"76","author":"Ireland","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115697_b0425","article-title":"Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer","volume":"12","author":"Comandatore","year":"2022","journal-title":"Diagnostics (basel)"},{"key":"10.1016\/j.addr.2025.115697_b0430","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/s41467-024-45753-7","article-title":"Exosomes define a local and systemic communication network in healthy pancreas and pancreatic ductal adenocarcinoma","volume":"15","author":"Adem","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115697_b0435","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/bjc.2017.18","article-title":"Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK","volume":"116","author":"Patel","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2025.115697_b0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2019.111543","article-title":"Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer","volume":"383","author":"Fang","year":"2019","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.addr.2025.115697_b0445","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41563-021-01085-1","article-title":"A microenvironment-inspired synthetic three-dimensional model for pancreatic ductal adenocarcinoma organoids","volume":"21","author":"Below","year":"2022","journal-title":"Nat. Mater."},{"key":"10.1016\/j.addr.2025.115697_b0450","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/gutjnl-2016-311954","article-title":"Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer","volume":"67","author":"Hessmann","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.addr.2025.115697_b0455","doi-asserted-by":"crossref","unstructured":"S. Dalin, M.R. Sullivan, A.N. Lau, B. Grauman-Boss, H.S. Mueller, E. Kreidl, S. Fenoglio, A. Luengo, J.A. Lees, M.G. Vander Heiden, D.A. Lauffenburger, M.T. Hemann, Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance, Cancer Res, 79 (2019) 5723-5733.","DOI":"10.1158\/0008-5472.CAN-19-0960"},{"key":"10.1016\/j.addr.2025.115697_b0460","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cell.2014.08.007","article-title":"Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy","volume":"159","author":"Sherman","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.addr.2025.115697_b0465","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12885-022-09272-2","article-title":"Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I\/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma","volume":"22","author":"Mizutani","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.addr.2025.115697_b0470","doi-asserted-by":"crossref","unstructured":"H.M. Kocher, B.-S. team, B. team, t. Precision-Panc, P. Sasieni, P. Corrie, M.G. McNamara, D. Sarker, F.E.M. Froeling, A. Christie, R. Gillmore, K. Khan, D. Propper, Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2, BMC Cancer, 25 (2025) 106.","DOI":"10.1186\/s12885-024-13333-z"},{"key":"10.1016\/j.addr.2025.115697_b0475","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.addr.2025.115697_b0480","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.addr.2025.115697_b0485","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2025.115697_b0490","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115697_b0495","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without Tremelimumab for patients with Metastatic Pancreatic Ductal Adenocarcinoma: a phase 2 Randomized Clinical Trial","volume":"5","author":"O'Reilly","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.addr.2025.115697_b0500","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2025.115697_b0505","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padron","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2025.115697_b0510","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1158\/1078-0432.CCR-17-3401","article-title":"Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer reveals three Distinct Subtypes with Prognostic\/Predictive significance","volume":"24","author":"Wartenberg","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115697_b0515","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/s41467-024-55424-2","article-title":"Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms","volume":"16","author":"Sivakumar","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115697_b0520","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/1078-0432.CCR-20-3141","article-title":"Composition, Spatial Characteristics, and Prognostic significance of Myeloid Cell Infiltration in Pancreatic Cancer","volume":"27","author":"Vayrynen","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115697_b0525","first-page":"978","article-title":"T-cell Localization, Activation, and Clonal expansion in Human Pancreatic Ductal Adenocarcinoma, Cancer","volume":"5","author":"Stromnes","year":"2017","journal-title":"Immunol. Res."},{"key":"10.1016\/j.addr.2025.115697_b0530","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/s43018-020-00121-4","article-title":"Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer","volume":"1","author":"Steele","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.addr.2025.115697_b0535","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1073\/pnas.1811067116","article-title":"Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer","volume":"116","author":"Blando","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2025.115697_b0540","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/bjc.2013.32","article-title":"Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer","volume":"108","author":"Ino","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2025.115697_b0545","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/ijc.32186","article-title":"Immunophenotypes of pancreatic ductal adenocarcinoma: Meta-analysis of transcriptional subtypes","volume":"145","author":"de Santiago","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.addr.2025.115697_b0550","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejca.2020.03.013","article-title":"The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis","volume":"132","author":"Orhan","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.addr.2025.115697_b0555","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41422-019-0195-y","article-title":"Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma","volume":"29","author":"Peng","year":"2019","journal-title":"Cell Res."},{"key":"10.1016\/j.addr.2025.115697_b0560","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1158\/2159-8290.CD-21-1248","article-title":"Single-Cell Sequencing reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer","volume":"12","author":"Schalck","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2025.115697_b0565","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41586-023-06685-2","article-title":"IL-1beta(+) macrophages fuel pathogenic inflammation in pancreatic cancer","volume":"623","author":"Caronni","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.addr.2025.115697_b0570","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.immuni.2021.07.007","article-title":"Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease","volume":"54","author":"Mulder","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2025.115697_b0575","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1126\/science.ade2292","article-title":"CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers","volume":"381","author":"Bill","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.addr.2025.115697_b0580","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1466767","article-title":"Single-cell transcriptome analysis identifies a novel tumor-associated macrophage subtype predicting better prognosis in pancreatic ductal adenocarcinoma","volume":"12","author":"Wang","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.addr.2025.115697_b0585","doi-asserted-by":"crossref","first-page":"17412","DOI":"10.1038\/s41598-024-68109-z","article-title":"CTHRC1(+) fibroblasts and SPP1(+) macrophages synergistically contribute to pro-tumorigenic tumor microenvironment in pancreatic ductal adenocarcinoma","volume":"14","author":"Li","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115697_b0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215925","article-title":"TGF-beta signaling networks in the tumor microenvironment","volume":"550","author":"Chan","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.addr.2025.115697_b0595","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/cam4.993","article-title":"Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma","volume":"6","author":"Zhang","year":"2017","journal-title":"Cancer Med."},{"key":"10.1016\/j.addr.2025.115697_b0600","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020395118","article-title":"IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions","volume":"118","author":"Mucciolo","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2025.115697_b0605","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1016\/j.cell.2021.07.020","article-title":"Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy","volume":"184","author":"Koikawa","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.addr.2025.115697_b0610","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1158\/2159-8290.CD-19-0958","article-title":"Regulatory T-cell Depletion Alters the Tumor Microenvironment and Accelerates Pancreatic Carcinogenesis","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2025.115697_b0615","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1136\/gutjnl-2018-317570","article-title":"Stromal protein betaig-h3 reprogrammes tumour microenvironment in pancreatic cancer","volume":"68","author":"Goehrig","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.addr.2025.115697_b0620","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2025.115697_b0625","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41467-021-20982-2","article-title":"Stromal-driven and Amyloid beta-dependent induction of neutrophil extracellular traps modulates tumor growth","volume":"12","author":"Munir","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115697_b0630","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","article-title":"The hallmarks of cancer immune evasion","volume":"42","author":"Galassi","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2025.115697_b0635","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41568-021-00375-9","article-title":"Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment","volume":"21","author":"Kerk","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2025.115697_b0640","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","article-title":"Barriers and opportunities in pancreatic cancer immunotherapy","volume":"8","author":"Ju","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.addr.2025.115697_b0645","article-title":"Redox-responsive metal-organic framework nanocapsules enhance tumor chemo-immunotherapy by modulating tumor metabolic reprogramming","volume":"31","author":"Dong","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.addr.2025.115697_b0650","doi-asserted-by":"crossref","unstructured":"V.S. LeBleu, B.G. Smaglo, K.K. Mahadevan, M.L. Kirtley, K.M. McAndrews, M. Mendt, S. Yang, A.S. Maldonado, H. Sugimoto, M.E. Salvatierra, L.M. Solis Soto, R. Finch, M. Gagea, A.C. Fluty, S.J. Ludtke, J.J. Lee, A.K. Jain, G. Varadhachary, R.T. Shroff, A. Maitra, E. Shpall, R. Kalluri, S. Pant, KRAS (G12D) -Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC Patients, medRxiv, (2025).","DOI":"10.1101\/2025.03.03.25322827"},{"key":"10.1016\/j.addr.2025.115697_b0655","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010057","article-title":"Depletion of tumor-derived CXCL5 improves T cell infiltration and anti-PD-1 therapy response in an obese model of pancreatic cancer","volume":"13","author":"Walsh","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.addr.2025.115697_b0660","article-title":"PD-L1 Immune Checkpoint Targeted Photoactivable Liposomes (iTPALs) Prime the Stroma of Pancreatic Tumors and Promote Self-delivery","volume":"13","author":"Bhandari","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.addr.2025.115697_b0665","doi-asserted-by":"crossref","first-page":"286","DOI":"10.62347\/ROAT5658","article-title":"TRAIL receptor agonist TLY012 in combination with PD-1 inhibition promotes tumor regression in an immune-competent mouse model of pancreatic ductal adenocarcinoma","volume":"15","author":"Louie","year":"2025","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.addr.2025.115697_b0670","first-page":"62","article-title":"Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1\/CXCR2 results in antitumor immunity and durable response in pancreatic cancer","volume":"4","author":"Gulhati","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.addr.2025.115697_b0675","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.addr.2025.115697_b0680","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.addr.2025.115697_b0685","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in developing personalized neoantigen cancer vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2025.115697_b0690","doi-asserted-by":"crossref","unstructured":"P. Singh, M.N. Khatib, R. R, M. Kaur, M. Srivastava, A. Barwal, G.V.S. Rajput, P. Rajput, R. Syed, G. Sharma, S. Kumar, M. Shabil, S. Pandey, M. Brar, G. Bushi, R. Mehta, S. Sah, K.W. Goh, P. Satapathy, A.M. Gaidhane, S.K. Samal, Advancements and challenges in personalized neoantigen-based cancer vaccines, Oncol Rev, 19 (2025) 1541326.","DOI":"10.3389\/or.2025.1541326"},{"key":"10.1016\/j.addr.2025.115697_b0695","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41416-022-02028-6","article-title":"CXCR1\/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer","volume":"128","author":"Piro","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2025.115697_b0700","doi-asserted-by":"crossref","first-page":"735","DOI":"10.15252\/emmm.201404346","article-title":"Pharmacological targeting of the protein synthesis mTOR\/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance","volume":"7","author":"Duluc","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.addr.2025.115697_b0705","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1007\/s00262-021-02853-3","article-title":"Enhanced anti-tumor efficacy of IL-7\/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models","volume":"70","author":"Goto","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.addr.2025.115697_b0710","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00432-022-04017-x","article-title":"CAR T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancer","volume":"148","author":"Zhu","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115697_b0715","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-23-3841","article-title":"Mesothelin CAR T Cells Secreting Anti-FAP\/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma","volume":"30","author":"Wehrli","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115697_b0720","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1111\/bph.16505","article-title":"Dual targeting chimeric antigen receptor cells enhance antitumour activity by overcoming T cell exhaustion in pancreatic cancer","volume":"181","author":"Ruixin","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.addr.2025.115697_b0725","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12967-023-04080-z","article-title":"FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer","volume":"21","author":"Liu","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.addr.2025.115697_b0730","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.addr.2025.115697_b0735","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115697_b0740","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12943-024-02184-8","article-title":"Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy","volume":"23","author":"Zheng","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.addr.2025.115697_b0745","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s10020-024-00996-4","article-title":"Leveraging CAR macrophages targeting c-Met for precision immunotherapy in pancreatic cancer: insights from single-cell multi-omics","volume":"30","author":"Hu","year":"2024","journal-title":"Mol. Med."},{"key":"10.1016\/j.addr.2025.115697_b0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113888","article-title":"In vivo FAP-CAR macrophages enhance chemotherapy and immunotherapy against pancreatic cancer by removing the fibrosis barrier","volume":"384","author":"Wang","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115697_b0755","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1038\/s41467-023-41470-9","article-title":"Metabolic Reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors","volume":"14","author":"Wang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115697_b0760","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","article-title":"A second-generation M1-polarized CAR macrophage with antitumor efficacy","volume":"25","author":"Lei","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2025.115697_b0765","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2025.115697_b0770","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2025.115697_b0775","doi-asserted-by":"crossref","unstructured":"N. Waddell, M. Pajic, A.M. Patch, D.K. Chang, K.S. Kassahn, P. Bailey, A.L. Johns, D. Miller, K. Nones, K. Quek, M.C. Quinn, A.J. Robertson, M.Z. Fadlullah, T.J. Bruxner, A.N. Christ, I. Harliwong, S. Idrisoglu, S. Manning, C. Nourse, E. Nourbakhsh, S. Wani, P.J. Wilson, E. Markham, N. Cloonan, M.J. Anderson, J.L. Fink, O. Holmes, S.H. Kazakoff, C. Leonard, F. Newell, B. Poudel, S. Song, D. Taylor, N. Waddell, S. Wood, Q. Xu, J. Wu, M. Pinese, M.J. Cowley, H.C. Lee, M.D. Jones, A.M. Nagrial, J. Humphris, L.A. Chantrill, V. Chin, A.M. Steinmann, A. Mawson, E.S. Humphrey, E.K. Colvin, A. Chou, C.J. Scarlett, A.V. Pinho, M. Giry-Laterriere, I. Rooman, J.S. Samra, J.G. Kench, J.A. Pettitt, N.D. Merrett, C. Toon, K. Epari, N.Q. Nguyen, A. Barbour, N. Zeps, N.B. Jamieson, J.S. Graham, S.P. Niclou, R. Bjerkvig, R. Grutzmann, D. Aust, R.H. Hruban, A. Maitra, C.A. Iacobuzio-Donahue, C.L. Wolfgang, R.A. Morgan, R.T. Lawlor, V. Corbo, C. Bassi, M. Falconi, G. Zamboni, G. Tortora, M.A. Tempero, I. Australian Pancreatic Cancer Genome, A.J. Gill, J.R. Eshleman, C. Pilarsky, A. Scarpa, E.A. Musgrove, J.V. Pearson, A.V. Biankin, S.M. Grimmond, Whole genomes redefine the mutational landscape of pancreatic cancer, Nature, 518 (2015) 495-501.","DOI":"10.1038\/nature14169"},{"key":"10.1016\/j.addr.2025.115697_b0780","doi-asserted-by":"crossref","unstructured":"A.V. Biankin, N. Waddell, K.S. Kassahn, M.C. Gingras, L.B. Muthuswamy, A.L. Johns, D.K. Miller, P.J. Wilson, A.M. Patch, J. Wu, D.K. Chang, M.J. Cowley, B.B. Gardiner, S. Song, I. Harliwong, S. Idrisoglu, C. Nourse, E. Nourbakhsh, S. Manning, S. Wani, M. Gongora, M. Pajic, C.J. Scarlett, A.J. Gill, A.V. Pinho, I. Rooman, M. Anderson, O. Holmes, C. Leonard, D. Taylor, S. Wood, Q. Xu, K. Nones, J.L. Fink, A. Christ, T. Bruxner, N. Cloonan, G. Kolle, F. Newell, M. Pinese, R.S. Mead, J.L. Humphris, W. Kaplan, M.D. Jones, E.K. Colvin, A.M. Nagrial, E.S. Humphrey, A. Chou, V.T. Chin, L.A. Chantrill, A. Mawson, J.S. Samra, J.G. Kench, J.A. Lovell, R.J. Daly, N.D. Merrett, C. Toon, K. Epari, N.Q. Nguyen, A. Barbour, N. Zeps, I. Australian Pancreatic Cancer Genome, N. Kakkar, F. Zhao, Y.Q. Wu, M. Wang, D.M. Muzny, W.E. Fisher, F.C. Brunicardi, S.E. Hodges, J.G. Reid, J. Drummond, K. Chang, Y. Han, L.R. Lewis, H. Dinh, C.J. Buhay, T. Beck, L. Timms, M. Sam, K. Begley, A. Brown, D. Pai, A. Panchal, N. Buchner, R. De Borja, R.E. Denroche, C.K. Yung, S. Serra, N. Onetto, D. Mukhopadhyay, M.S. Tsao, P.A. Shaw, G.M. Petersen, S. Gallinger, R.H. Hruban, A. Maitra, C.A. Iacobuzio-Donahue, R.D. Schulick, C.L. Wolfgang, R.A. Morgan, R.T. Lawlor, P. Capelli, V. Corbo, M. Scardoni, G. Tortora, M.A. Tempero, K.M. Mann, N.A. Jenkins, P.A. Perez-Mancera, D.J. Adams, D.A. Largaespada, L.F. Wessels, A.G. Rust, L.D. Stein, D.A. Tuveson, N.G. Copeland, E.A. Musgrove, A. Scarpa, J.R. Eshleman, T.J. Hudson, R.L. Sutherland, D.A. Wheeler, J.V. Pearson, J.D. McPherson, R.A. Gibbs, S.M. Grimmond, Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes, Nature, 491 (2012) 399-405.","DOI":"10.1038\/nature11547"},{"key":"10.1016\/j.addr.2025.115697_b0785","doi-asserted-by":"crossref","first-page":"6744","DOI":"10.1038\/ncomms7744","article-title":"Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets","volume":"6","author":"Witkiewicz","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115697_b0790","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm.2344","article-title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","volume":"17","author":"Collisson","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2025.115697_b0795","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1038\/s41467-018-04383-6","article-title":"Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes","volume":"9","author":"Lomberk","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115697_b0800","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2018.08.033","article-title":"Stratification of Pancreatic Ductal Adenocarcinomas based on Tumor and Microenvironment Features","volume":"155","author":"Puleo","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2025.115697_b0805","doi-asserted-by":"crossref","first-page":"10100","DOI":"10.1038\/s41467-024-54438-0","article-title":"Multimodal single cell-resolved spatial proteomics reveal pancreatic tumor heterogeneity","volume":"15","author":"Xu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115697_b0810","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41568-021-00418-1","article-title":"Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data","volume":"22","author":"Connor","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2025.115697_b0815","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1158\/2767-9764.CRC-23-0489","article-title":"Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer","volume":"4","author":"Dimitrieva","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.addr.2025.115697_b0820","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s43018-023-00526-x","article-title":"Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy","volume":"4","author":"Barthel","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.addr.2025.115697_b0825","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1158\/1078-0432.CCR-24-2183","article-title":"Human Pancreatic Cancer Single-Cell Atlas reveals Association of CXCL10+ Fibroblasts and Basal Subtype Tumor Cells","volume":"31","author":"Loveless","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115697_b0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100726","article-title":"Spatial Transcriptomics reveals Cancer and Stromal Cell Heterogeneity between Center and Invasive Front of Pancreatic Cancer","volume":"38","author":"Alver","year":"2025","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.addr.2025.115697_b0835","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41588-019-0566-9","article-title":"Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution","volume":"52","author":"Chan-Seng-Yue","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2025.115697_b0840","first-page":"724","article-title":"A New Reservoir of Stromal Targets in Pancreatic Cancer, Trends","volume":"5","author":"Pereira","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2025.115697_b0845","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm.4082","article-title":"Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression","volume":"22","author":"Laklai","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2025.115697_b0850","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1038\/s41467-018-07339-y","article-title":"Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels","volume":"9","author":"Novo","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115697_b0855","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1038\/s41388-022-02368-w","article-title":"Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer","volume":"41","author":"Datta","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.addr.2025.115697_b0860","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2025631118","article-title":"TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment","volume":"118","author":"Maddalena","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2025.115697_b0865","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.celrep.2019.12.028","article-title":"Cancer-specific loss of p53 leads to a Modulation of Myeloid and T Cell responses","volume":"30","author":"Blagih","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2025.115697_b0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109578","article-title":"Gain-of-function p53(R172H) mutation drives accumulation of neutrophils in pancreatic tumors, promoting resistance to immunotherapy","volume":"36","author":"Siolas","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2025.115697_b0875","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1158\/2159-8290.CD-22-1046","article-title":"Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer","volume":"13","author":"Bianchi","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2025.115697_b0880","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-24-2330","article-title":"SMAD4 and KRAS Status Shape Cancer Cell-Stromal Crosstalk and Therapeutic Response in Pancreatic Cancer","author":"Lloyd","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115697_b0885","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1158\/2159-8290.CD-20-1826","article-title":"MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma","volume":"12","author":"Maddipati","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2025.115697_b0890","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","article-title":"Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer","volume":"13","author":"Kemp","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2025.115697_b0895","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","article-title":"Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer","volume":"14","author":"Dilly","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2025.115697_b0900","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","article-title":"KRAS(G12D) inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8(+) T cells","volume":"41","author":"Mahadevan","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2025.115697_b0905","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2767-9764.CRC-24-0172","article-title":"Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with combined SOS1 and MEK Inhibition for improved Immunotherapy Response","volume":"4","author":"Norgard","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.addr.2025.115697_b0910","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nature25459","article-title":"Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes","volume":"554","author":"Mueller","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.addr.2025.115697_b0915","doi-asserted-by":"crossref","unstructured":"K.K. Mahadevan, A.S. Maldonado, B. Li, A.A. Bickert, A. Perdyan, S.V. Kumbhar, S. Piya, A. Sockwell, S.J. Morse, K. Arian, H. Sugimoto, S. Shalapour, D.S. Hong, T.P. Heffernan, A. Maitra, R. Kalluri, Inhibitors of oncogenic Kras specifically prime CTLA4 blockade to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancer, bioRxiv, (2025).","DOI":"10.1101\/2025.02.28.640711"},{"key":"10.1016\/j.addr.2025.115697_b0920","doi-asserted-by":"crossref","first-page":"6513","DOI":"10.1038\/s41467-022-34081-3","article-title":"BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling","volume":"13","author":"Shaashua","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115697_b0925","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101115","article-title":"Dynamic immunoediting by macrophages in homologous recombination deficiency-stratified pancreatic ductal adenocarcinoma","volume":"76","author":"Hong","year":"2024","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.addr.2025.115697_b0930","doi-asserted-by":"crossref","unstructured":"R. Russell, L. Perkhofer, S. Liebau, Q. Lin, A. Lechel, F.M. Feld, E. Hessmann, J. Gaedcke, M. G\u00fcthle, M. Zenke, D. Hartmann, G. von Figura, S. E. Weissinger, K-L. Rudolph, P. M\u00f6ller, J.K. Lennerz, T. Seufferlein, M. Wagner, A. Kleger, Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition, Nat Commun. 2015 Jul 29;6:7677.","DOI":"10.1038\/ncomms8677"},{"key":"10.1016\/j.addr.2025.115697_b0935","doi-asserted-by":"crossref","unstructured":"R.M. Samstein, C. Krishna, X. Ma, X. Pei, K.W. Lee, V. Makarov, F. Kuo, J. Chung, R.M. Srivastava, T.A. Purohit, D.R. Hoen, R. Mandal, J. Setton, W. Wu, R. Shah, B. Qeriqi, Q. Chang, S. Kendall, L. Braunstein, B. Weigelt, P. Blecua Carrillo Albornoz, L.G.T. Morris, D.L. Mandelker, J.S. Reis-Filho, E. de Stanchina, S.N. Powell, T.A. Chan, N. Riaz, Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy, Nat Cancer, 1 (2021) 1188-1203.","DOI":"10.1038\/s43018-020-00139-8"},{"key":"10.1016\/j.addr.2025.115697_b0940","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000942","article-title":"Molecular characteristics of BRCA1\/2 and PALB2 mutations in pancreatic ductal adenocarcinoma","volume":"5","author":"Seeber","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.addr.2025.115697_b0945","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226714","article-title":"Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains","volume":"14","author":"Park","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2025.115697_b0950","article-title":"Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma with Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review","volume":"6","author":"Lundy","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.addr.2025.115697_b0955","doi-asserted-by":"crossref","unstructured":"D. Cui Zhou, R.G. Jayasinghe, S. Chen, J.M. Herndon, M.D. Iglesia, P. Navale, M.C. Wendl, W. Caravan, K. Sato, E. Storrs, C.K. Mo, J. Liu, A.N. Southard-Smith, Y. Wu, N. Naser Al Deen, J.M. Baer, R.S. Fulton, M.A. Wyczalkowski, R. Liu, C.C. Fronick, L.A. Fulton, A. Shinkle, L. Thammavong, H. Zhu, H. Sun, L.B. Wang, Y. Li, C. Zuo, J.F. McMichael, S.R. Davies, E.L. Appelbaum, K.J. Robbins, S.E. Chasnoff, X. Yang, A.N. Reeb, C. Oh, M. Serasanambati, P. Lal, R. Varghese, J.R. Mashl, J. Ponce, N.V. Terekhanova, L. Yao, F. Wang, L. Chen, M. Schnaubelt, R.J. Lu, J.K. Schwarz, S.V. Puram, A.H. Kim, S.K. Song, K.I. Shoghi, K.S. Lau, T. Ju, K. Chen, D. Chatterjee, W.G. Hawkins, H. Zhang, S. Achilefu, M.G. Chheda, S.T. Oh, W.E. Gillanders, F. Chen, D.G. DeNardo, R.C. Fields, L. Ding, Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer, Nat Genet, 54 (2022) 1390-1405.","DOI":"10.1038\/s41588-022-01157-1"},{"key":"10.1016\/j.addr.2025.115697_b0960","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41568-022-00530-w","article-title":"Epithelial and stromal co-evolution and complicity in pancreatic cancer","volume":"23","author":"Hingorani","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2025.115697_b0965","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ccell.2024.02.017","article-title":"Mapping functional to morphological variation reveals the basis of regional extracellular matrix subversion and nerve invasion in pancreatic cancer","volume":"42","author":"Di Chiaro","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2025.115697_b0970","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cell.2019.05.012","article-title":"Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer","volume":"178","author":"Ligorio","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.addr.2025.115697_b0975","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1053\/j.gastro.2023.05.036","article-title":"Spatially Resolved Multi-Omics Single-Cell analyses Inform Mechanisms of Immune Dysfunction in Pancreatic Cancer","volume":"165","author":"Yousuf","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2025.115697_b0980","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41587-019-0392-8","article-title":"Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas","volume":"38","author":"Moncada","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2025.115697_b0985","article-title":"Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma","volume":"4","author":"Mascharak","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.addr.2025.115697_b0990","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41416-021-01639-9","article-title":"Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5","volume":"126","author":"Nakajima","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2025.115697_b0995","first-page":"337","article-title":"Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-paclitaxel Reduces the Number of Cancer-associated Fibroblasts through Depletion of Pancreatic Stroma","volume":"38","author":"Miyashita","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.addr.2025.115697_b1000","doi-asserted-by":"crossref","unstructured":"P. Bailey, D.K. Chang, K. Nones, A.L. Johns, A.M. Patch, M.C. Gingras, D.K. Miller, A.N. Christ, T.J. Bruxner, M.C. Quinn, C. Nourse, L.C. Murtaugh, I. Harliwong, S. Idrisoglu, S. Manning, E. Nourbakhsh, S. Wani, L. Fink, O. Holmes, V. Chin, M.J. Anderson, S. Kazakoff, C. Leonard, F. Newell, N. Waddell, S. Wood, Q. Xu, P.J. Wilson, N. Cloonan, K.S. Kassahn, D. Taylor, K. Quek, A. Robertson, L. Pantano, L. Mincarelli, L.N. Sanchez, L. Evers, J. Wu, M. Pinese, M.J. Cowley, M.D. Jones, E.K. Colvin, A.M. Nagrial, E.S. Humphrey, L.A. Chantrill, A. Mawson, J. Humphris, A. Chou, M. Pajic, C.J. Scarlett, A.V. Pinho, M. Giry-Laterriere, I. Rooman, J.S. Samra, J.G. Kench, J.A. Lovell, N.D. Merrett, C.W. Toon, K. Epari, N.Q. Nguyen, A. Barbour, N. Zeps, K. Moran-Jones, N.B. Jamieson, J.S. Graham, F. Duthie, K. Oien, J. Hair, R. Grutzmann, A. Maitra, C.A. Iacobuzio-Donahue, C.L. Wolfgang, R.A. Morgan, R.T. Lawlor, V. Corbo, C. Bassi, B. Rusev, P. Capelli, R. Salvia, G. Tortora, D. Mukhopadhyay, G.M. Petersen, I. Australian Pancreatic Cancer Genome, D.M. Munzy, W.E. Fisher, S.A. Karim, J.R. Eshleman, R.H. Hruban, C. Pilarsky, J.P. Morton, O.J. Sansom, A. Scarpa, E.A. Musgrove, U.M. Bailey, O. Hofmann, R.L. Sutherland, D.A. Wheeler, A.J. Gill, R.A. Gibbs, J.V. Pearson, N. Waddell, A.V. Biankin, S.M. Grimmond, Genomic analyses identify molecular subtypes of pancreatic cancer, Nature, 531 (2016) 47-52.","DOI":"10.1038\/nature16965"},{"key":"10.1016\/j.addr.2025.115697_b1005","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1158\/1078-0432.CCR-22-0308","article-title":"Defactinib, Pembrolizumab, and Gemcitabine in patients with Advanced Treatment Refractory Pancreatic Cancer: a phase I Dose Escalation and expansion Study","volume":"28","author":"Wang-Gillam","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115697_b1010","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1158\/2159-8290.CD-22-0192","article-title":"Stromal Reprogramming by FAK Inhibition Overcomes Radiation Resistance to allow for Immune Priming and Response to Checkpoint Blockade","volume":"12","author":"Lander","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2025.115697_b1015","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41416-018-0246-z","article-title":"Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer","volume":"119","author":"Melisi","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2025.115697_b1020","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002068","article-title":"Safety and activity of the TGFbeta receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer","volume":"9","author":"Melisi","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.addr.2025.115697_b1025","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1200\/JCO.23.01965","article-title":"Randomized phase II Study of Nab-Paclitaxel and Gemcitabine with or without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia","volume":"43","author":"Chen","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115697_b1030","doi-asserted-by":"crossref","first-page":"8471","DOI":"10.3748\/wjg.v20.i26.8471","article-title":"Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluation","volume":"20","author":"Coleman","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.addr.2025.115697_b1035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.21037\/cco.2017.06.15","article-title":"Preclinical models of pancreatic ductal adenocarcinoma","volume":"6","author":"Krempley","year":"2017","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115697_b1040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/bs.acr.2023.02.002","article-title":"In vivo models of pancreatic ductal adenocarcinoma","volume":"159","author":"Vudatha","year":"2023","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.addr.2025.115697_b1045","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1053\/j.gastro.2004.12.036","article-title":"Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells","volume":"128","author":"Bachem","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2025.115697_b1050","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00423-008-0279-5","article-title":"Pancreatic stellate cells\u2013role in pancreas cancer","volume":"393","author":"Bachem","year":"2008","journal-title":"Langenbecks Arch. Surg."},{"key":"10.1016\/j.addr.2025.115697_b1055","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1242\/jcs.00503","article-title":"Modeling tissue-specific signaling and organ function in three dimensions","volume":"116","author":"Schmeichel","year":"2003","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.addr.2025.115697_b1060","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.stem.2021.03.005","article-title":"Modeling plasticity and dysplasia of pancreatic ductal organoids derived from human pluripotent stem cells","volume":"28","author":"Breunig","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.addr.2025.115697_b1065","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.stem.2021.03.022","article-title":"Commitment and oncogene-induced plasticity of human stem cell-derived pancreatic acinar and ductal organoids","volume":"28","author":"Huang","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.addr.2025.115697_b1070","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202256045","article-title":"The regulation of human blastoid research: a bioethical discussion of the limits of regulation","volume":"23","author":"Sawai","year":"2022","journal-title":"EMBO Rep."},{"issue":"Suppl 2","key":"10.1016\/j.addr.2025.115697_b1075","first-page":"S2","article-title":"Clarifying the Ethics and Oversight of Chimeric Research","volume":"52","author":"Johnston","year":"2022","journal-title":"Hastings Cent. Rep."},{"key":"10.1016\/j.addr.2025.115697_b1080","first-page":"21","article-title":"Organoid-based precision medicine in pancreatic cancer, united European","volume":"13","author":"Beutel","year":"2025","journal-title":"Gastroenterol. J."},{"key":"10.1016\/j.addr.2025.115697_b1085","first-page":"445","article-title":"State-matched organoid models to fight pancreatic cancer, Trends","volume":"8","author":"Melzer","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2025.115697_b1090","doi-asserted-by":"crossref","first-page":"26580","DOI":"10.1073\/pnas.1911273116","article-title":"Pancreatic cancer organoids recapitulate disease and allow personalized drug screening","volume":"116","author":"Driehuis","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2025.115697_b1095","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1016\/j.cell.2021.11.017","article-title":"Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer","volume":"184","author":"Raghavan","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.addr.2025.115697_b1100","doi-asserted-by":"crossref","first-page":"12214","DOI":"10.1096\/fj.202000363RR","article-title":"Basal-like and classical cells coexist in pancreatic cancer revealed by single-cell analysis on biopsy-derived pancreatic cancer organoids from the classical subtype","volume":"34","author":"Juiz","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.addr.2025.115697_b1105","article-title":"Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma, Nat","author":"Papargyriou","year":"2024","journal-title":"Biomed. Eng."},{"key":"10.1016\/j.addr.2025.115697_b1110","article-title":"Ethical challenges in Organoid Use","volume":"10","author":"Mollaki","year":"2021","journal-title":"BioTech (basel)"},{"key":"10.1016\/j.addr.2025.115697_b1115","doi-asserted-by":"crossref","unstructured":"J. Gout, L. Perkhofer, J. Lindenmayer, Y.J. Resheq, J.D. Schwab, J.M. Kraus, E. Roger, D. Srinivasan, E. Zimmer, B. Mayer, R. Marienfeld, N.T. Gaisa, J.K. K\u00fchlwein, M. H\u00e4nle, T.J. Ettrich, K.M. Danzer, A.K. Beutel, B. Kong, C. Michalski, A.L. Mihaljevic, N.N. Rahbari, M. Kornmann, H.A. Kestler, T. Seufferlein, A. Kleger, Pancreatic cancer patient-derived organoids capture therapy response and tumor evolution, bioRxiv, (2025) 2025.2004.2024.650216.","DOI":"10.1101\/2025.04.24.650216"},{"key":"10.1016\/j.addr.2025.115697_b1120","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s13046-022-02519-7","article-title":"Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system","volume":"41","author":"Schuth","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115697_b1125","doi-asserted-by":"crossref","first-page":"13051","DOI":"10.1007\/s00432-023-05100-7","article-title":"In-vitro model to mimic T cell subset change in human PDAC organoid co-culture","volume":"149","author":"Knoblauch","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115697_b1130","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13046-025-03332-8","article-title":"Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatment","volume":"44","author":"Li","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115697_b1135","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122838","article-title":"A pancreatic cancer organoid incorporating macrophages reveals the correlation between the diversity of tumor-associated macrophages and cancer cell survival","volume":"314","author":"Tabe","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2025.115697_b1140","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122631","article-title":"A bioprinted sea-and-island multicellular model for dissecting human pancreatic tumor-stroma reciprocity and adaptive metabolism","volume":"310","author":"Li","year":"2024","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2025.115697_b1145","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202402060","article-title":"Tumoroid-On-a-Plate (ToP): Physiologically Relevant Cancer Model Generation and Therapeutic Screening","volume":"14","author":"Seyfoori","year":"2025","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.addr.2025.115697_b1150","series-title":"Modelling of the multicellular tumor microenvironment of pancreatic ductal adenocarcinoma","author":"Deipenbrock","year":"2025"},{"key":"10.1016\/j.addr.2025.115697_b1155","doi-asserted-by":"crossref","DOI":"10.3791\/66625","article-title":"Growing Desmoplastic Three-Dimensional Pancreatic Cancer Spheroids from Co-Culture","author":"Bahl","year":"2024","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.addr.2025.115697_b1160","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1021\/acsabm.0c00791","article-title":"3D Bioprinting of Tumor Models for Cancer Research","volume":"3","author":"Kang","year":"2020","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.addr.2025.115697_b1165","doi-asserted-by":"crossref","first-page":"10547","DOI":"10.1021\/acs.chemrev.9b00789","article-title":"Bioprinting: from Tissue and Organ Development to in Vitro Models","volume":"120","author":"Mota","year":"2020","journal-title":"Chem. Rev."},{"key":"10.1016\/j.addr.2025.115697_b1170","doi-asserted-by":"crossref","DOI":"10.3390\/diseases12090206","article-title":"A 3D Bio-Printed-based Model for Pancreatic Ductal Adenocarcinoma","volume":"12","author":"Godier","year":"2024","journal-title":"Diseases"},{"key":"10.1016\/j.addr.2025.115697_b1175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bprint.2024.e00374","article-title":"3D bioprinting of multicellular tumor spheroids in photocrosslinkable hyaluronan-gelatin for engineering pancreatic cancer microenvironment","author":"Yang","year":"2024","journal-title":"Bioprinting"},{"key":"10.1016\/j.addr.2025.115697_b1180","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejpb.2021.11.005","article-title":"Peptide dendrimers as potentiators of conventional chemotherapy in the treatment of pancreatic cancer in a mouse model","volume":"170","author":"Huang","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2025.115697_b1185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1571182","article-title":"Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study","volume":"16","author":"Oyama","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2025.115697_b1190","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1021\/acsabm.4c00658","article-title":"Hybrid Nanoparticles of Extracellular Vesicles and Gemcitabine Prodrug-Loaded Liposomes with Enhanced Targeting Ability for Effective PDAC Treatment","volume":"7","author":"Kim","year":"2024","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.addr.2025.115697_b1195","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jcis.2023.12.166","article-title":"Enhancing pancreatic ductal adenocarcinoma (PDAC) therapy with targeted carbon nano-onion (CNO)-mediated delivery of gemcitabine (GEM)-derived prodrugs","volume":"659","author":"Bartkowski","year":"2024","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.addr.2025.115697_b1200","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040952","article-title":"CCN-Based Therapeutic Peptides Modify Pancreatic Ductal Adenocarcinoma Microenvironment and Decrease Tumor Growth in Combination with Chemotherapy","volume":"9","author":"Resovi","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.addr.2025.115697_b1205","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1039\/D0TB00017E","article-title":"Theranostic nanoparticles enabling the release of phosphorylated gemcitabine for advanced pancreatic cancer therapy","volume":"8","author":"Wang","year":"2020","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.addr.2025.115697_b1210","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202104449","article-title":"Advanced Nanoengineering Approach for Target-specific, Spatiotemporal, and Ratiometric delivery of Gemcitabine-Cisplatin Combination for improved Therapeutic Outcome in Pancreatic Cancer","volume":"18","author":"Tarannum","year":"2022","journal-title":"Small"},{"key":"10.1016\/j.addr.2025.115697_b1215","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1021\/acsabm.5c00562","article-title":"Hybrid Nanocarrier Delivers Immuno-Photothermal Therapy to Modulate Pancreatic Tumor Microenvironment","volume":"8","author":"Robert","year":"2025","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.addr.2025.115697_b1220","article-title":"Dual mRNA nanoparticles strategy for enhanced pancreatic cancer treatment and beta-elemene combination therapy","volume":"122","author":"Zhu","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2025.115697_b1225","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17040449","article-title":"Nanomedicine in the Diagnosis and Treatment of Pancreatic Cancer","volume":"17","author":"Guo","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2025.115697_b1230","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s41467-024-45710-4","article-title":"A microfluidic platform integrating functional vascularized organoids-on-chip","volume":"15","author":"Quintard","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115697_b1235","article-title":"Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy","volume":"11","author":"Choi","year":"2024","journal-title":"Adv Sci (weinh)"},{"key":"10.1016\/j.addr.2025.115697_b1240","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41597-024-03631-3","article-title":"A Curated Cell Life Imaging Dataset of Immune-enriched Pancreatic Cancer Organoids with Pre-trained AI Models","volume":"11","author":"Kulkarni","year":"2024","journal-title":"Sci. Data"},{"key":"10.1016\/j.addr.2025.115697_b1245","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/s41592-025-02685-4","article-title":"Digitalized organoids: integrated pipeline for high-speed 3D analysis of organoid structures using multilevel segmentation and cellular topology","volume":"22","author":"Ong","year":"2025","journal-title":"Nat. Methods"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X25001826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X25001826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:22:16Z","timestamp":1778674936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X25001826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":249,"alternative-id":["S0169409X25001826"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2025.115697","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor microenvironment subtyping in pancreatic ductal adenocarcinoma: New avenues for personalized therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2025.115697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115697"}}